Group 1 - The core point of the article is that TianKang (SZ 301263) announced its subsidiary, Shandong Huabo Kaisheng Biotechnology Co., Ltd., participated in the 11th batch of national centralized drug procurement and is expected to be selected for the procurement [1] - For the fiscal year 2024, TianKang's revenue composition is as follows: pharmaceutical agency accounts for 61.1%, pharmaceutical manufacturing for 37.28%, pharmaceutical technology services for 1.51%, and other businesses for 0.12% [1] - As of the report, TianKang's market capitalization is 13.6 billion yuan [1] Group 2 - The A-share market has surpassed 4000 points, marking a significant resurgence after a decade of stagnation, with technology leading the market's transformation into a "slow bull" new pattern [1]
泰恩康：华铂凯盛产品拟中选本次集中采购